Breathe Technologies Inc, a manufacturer of innovative technology solutions for people with respiratory conditions, including sleep apnea, has secured $23 million in Series C financing. In its push into the respiratory market, the company has also tapped industry leader John L. Miclot as chairman of the board.
"Our strong team of investors, the addition of John Miclot as chairman, and recent FDA clearance further validate that Breathe is well positioned to bring breakthrough solutions to the respiratory markets," said Gregory J. Kapust, president and CEO of Breathe Technologies. "The Series C financing will fund commercialization of Breathe’s ultralight, mobile ventilation system for the millions of people worldwide with breathing challenges, such as COPD (chronic obstructive pulmonary disease). We will also continue development of our novel solutions for the sleep-disordered breathing market."
Chairman John Miclot, who was instrumental in building Respironics into a global leader in the sleep and respiratory markets, believes there is an extraordinary opportunity for innovation in the respiratory industry. "When I was introduced to Breathe’s products and development plans, it was clear this company had great potential to dramatically alter this industry’s landscape," stated Miclot, who became president and CEO of Respironics in 2003 and led the company’s $5.2 billion sale to Philips in March 2008. He subsequently served as CEO of Philips Home Healthcare Solutions and is currently an executive-in-residence at Warburg Pincus, serving on the boards of Wright Medical Group, ev3, and Dentsply.